Entresto Shortage Update: What Patients Need to Know in 2026

If your Entresto prescription keeps hitting roadblocks, you're not imagining things. Sacubitril/valsartan has gone through significant supply disruptions tied to the brand-to-generic transition. Here is a complete 2026 update on the availability situation, what's driving it, and what you can do to protect your access.

Is There a Formal Entresto Shortage in 2026?

No. As of 2026, the FDA has not listed Entresto or generic sacubitril/valsartan in its Drug Shortage Database. However, the line between "no official shortage" and "can't fill my prescription" is often blurry for patients. Localized gaps, pharmacy stocking issues, and insurance delays can all create the practical effect of a shortage — even without a formal designation.

What Changed in 2025–2026: The Generic Transition

The biggest change affecting Entresto availability is the expiration of Novartis's core U.S. patent in July 2025 and the arrival of generic sacubitril/valsartan. The FDA approved generics starting in May 2024, and multiple manufacturers — including Novadoz Pharmaceuticals, Camber, Ascend, and Macleods Pharma — began producing the drug.

While this is ultimately good news for availability and cost, the transition created a "messy middle" period where:

Some pharmacies stock the brand but not the generic (or vice versa)

Insurance plans are shifting coverage from brand to generic, causing prescription confusion and rejects

Not all generic manufacturers have reached full production capacity yet

Why Sacubitril/Valsartan Was Always at Risk for Supply Disruptions

Entresto's complex co-crystal formulation — two active pharmaceutical ingredients crystallized together in a precise 1:1 molar ratio — is technically demanding to manufacture. This complexity made the supply chain more fragile than typical single-compound tablets, and production disruptions had outsized effects on shelf availability. Now that multiple generic manufacturers share production, this fragility is diminishing.

Demand Has Continued to Rise

Novartis reported $7.8 billion in Entresto global sales in 2024. Heart failure affects approximately 6 million Americans, and current cardiology guidelines from the ACC/AHA recommend sacubitril/valsartan as the preferred ARNI in the four-drug "quadruple therapy" regimen for HFrEF. As guideline adoption increases, more patients are being started on the drug each year — putting steady upward pressure on demand.

Medicare Pricing Changes Affecting Entresto in 2026

Entresto was among the first 10 drugs selected for Medicare price negotiation under the Inflation Reduction Act. The negotiated maximum fair price for Medicare Part D beneficiaries is approximately $295 per 30-day supply, effective in 2026. This is a significant reduction from the brand-name list price of $600–$700 per month. Additionally, Medicare's $2,000 annual out-of-pocket cap (effective 2025) limits total spending for Part D beneficiaries.

How to Protect Your Entresto Supply in 2026

Here are steps you can take today to minimize disruptions:

Accept the generic. Generic sacubitril/valsartan is bioequivalent to Entresto and is available from multiple manufacturers. If you're brand-only, ask your doctor whether the generic is appropriate for you.

Refill early. Don't wait until the last pill. Refill your prescription 7–10 days before running out to give yourself time to search if your usual pharmacy is out of stock.

Consider mail order. Mail-order pharmacies often carry wider inventory and allow 90-day supplies. This reduces the frequency of refill searches.

Use medfinder if you hit a wall. medfinder contacts pharmacies near you to check which ones can fill your sacubitril/valsartan prescription, texting you the results so you don't have to make dozens of calls yourself.

The Outlook Is Getting Better

With multiple generic manufacturers now producing sacubitril/valsartan and the brand patent fully expired, the long-term supply picture is improving. Pharmacists with established supply chains report that generic sacubitril/valsartan can typically be ordered and delivered next business day. Read more about why Entresto has been hard to find and how to find it in stock near you.